Clinical trial design to target ageing and multimorbidity
Oxford Academic Health Science Network, University of Oxford, England, United Kingdom
Societies across the world have increasing proportions of older citizens, with increases in both disability-free life expectancy and disabled life expectancy. Disability in older age is usually associated with multimorbidity and/or frailty. The pharmaceutical industry currently focuses its efforts on developing drugs for single diseases. However it may be possible to develop single therapeutic agents that ore targeted at processes that drive the development and progression of multimorbidity and frailty associated with ageing. Potential ageing targets are inflammation, cellular senescence, DNA damage and repair and metabolic dysfunction.
Developing therapies for multimorbidity requires a different co-ordinated approach from academia and industry using opportunities created by developments in geroscience, biomarker development, and artificial intelligence analyse of clinical datasets.